CAR-T Cells Targeting Immune Checkpoint Pathway Players

Abstract

CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells. The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.